<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446901</url>
  </required_header>
  <id_info>
    <org_study_id>WCRF 2004/21</org_study_id>
    <secondary_id>CMO nr. 2007/003</secondary_id>
    <secondary_id>SePros 2006/02</secondary_id>
    <secondary_id>NL14694.091.07</secondary_id>
    <nct_id>NCT00446901</nct_id>
  </id_info>
  <brief_title>Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression</brief_title>
  <acronym>SePros</acronym>
  <official_title>Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Cancer Research Fund International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether selenium supplementation leads to changes in&#xD;
      selenium levels and gene expression profiles in prostate tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Prostate cancer is a frequently observed malignancy in men, especially in elderly&#xD;
      men. Besides diagnosis and treatment, also prevention of prostate cancer is an important&#xD;
      point of interest to reduce the incidence and mortality of prostate cancer. Selenium is&#xD;
      considered to be a promising chemopreventive agent for prostate cancer. Exact mechanisms of&#xD;
      chemoprevention by selenium are not fully understood. However, it is expected that selenium&#xD;
      (among other effects) directly affects gene expression in the prostate.&#xD;
&#xD;
      Objective: The aim of this study is to get insight into bioavailability of selenium in&#xD;
      prostate tissue and changes of gene expression profiles that might be responsible for&#xD;
      selenium-induced chemoprevention. To meet this objective, the relationship between dietary&#xD;
      selenium intake and changes in gene expression profiles, tissue selenium levels and blood&#xD;
      flow in prostate tissue will be examined.&#xD;
&#xD;
      Study design: The present study is designed as a double-blind, randomized and&#xD;
      placebo-controlled intervention trial. Blood samples, toenails, questionnaires, MR images and&#xD;
      surgical specimens will be collected to examine effects of selenium supplementation.&#xD;
&#xD;
      Study population: The study population will consist of 60 men, diagnosed with prostate cancer&#xD;
      and scheduled for radical prostatectomy. Written informed consent will be obtained from each&#xD;
      participant.&#xD;
&#xD;
      Intervention: Participants will receive 300 ug selenium / day or a placebo during 5 weeks&#xD;
      prior to radical prostatectomy. Selenium will be supplemented in the form of selenized yeast&#xD;
      tablets (SelenoPrecise, Pharma Nord).&#xD;
&#xD;
      Main study parameters: Levels of selenium in prostate tissue and changes in prostate gene&#xD;
      expression profiles of participants supplemented with selenium or placebo, compared before&#xD;
      and after the short intervention period, will be considered as the main parameters of the&#xD;
      present study. Besides gene expression profiles in prostate tissue, also gene expression&#xD;
      profiles of peripheral mononuclear cells (PBMC), levels of selenium in blood and toenails and&#xD;
      blood flow and permeability of blood vessels of prostate tissue will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>selenium levels in prostate tissue</measure>
    <time_frame>after 5 weeks of intervention with selenium or placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in gene expression profiles in prostate tissue</measure>
    <time_frame>after 5 weeks of intervention with selenium or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in blood flow, vessel permeability and exocrine functionality</measure>
    <time_frame>after 5 weeks of intervention with selenium or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in gene expression profiles in blood cells</measure>
    <time_frame>after 5 weeks of intervention with selenium or placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium (selenized yeast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selenium (selenized yeast) tablets, 300 ug/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>Selenized yeast, 300 ug/day</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Selenium (selenized yeast)</arm_group_label>
    <other_name>SelenoPrecise, PharmaNord</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  biopsy proven prostate cancer&#xD;
&#xD;
          -  scheduled for radical prostatectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  liver diseases (e.g. hepatitis)&#xD;
&#xD;
          -  kidney diseases&#xD;
&#xD;
          -  inflammatory bowel diseases&#xD;
&#xD;
          -  use of dietary supplements containing selenium&#xD;
&#xD;
          -  adjuvant therapy for prostate cancer (e.g. hormonal therapy, HIFU)&#xD;
&#xD;
          -  previously or concurrent diagnosed with cancer, other than prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.A. Witjes, Md PhD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center St Radboud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L.A.L.M. Kiemeney, PhD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center St Radboud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. van 't Veer, PhD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Wageningen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L.A. Afman, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wageningen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wageningen University</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6700 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <last_update_submitted>March 11, 2011</last_update_submitted>
  <last_update_submitted_qc>March 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2011</last_update_posted>
  <responsible_party>
    <organization>Wageningen University</organization>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Selenium</keyword>
  <keyword>Chemoprevention</keyword>
  <keyword>Gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

